Assessing prophylactic use and clinical outcomes in hemophilia A patients treated with rVIII‐SingleChain and other common rFVIII products in Germany

OBJECTIVE: To evaluate real‐world outcomes with rVIII‐SingleChain and other commonly used recombinant FVIII (rFVIII) products. METHODS: Hemophilia treatment centers in Germany (n = 21) contributed patient chart data. Inclusion criteria were prophylactic treatment with one of five rFVIII products for...

Descripción completa

Detalles Bibliográficos
Autores principales: Olivieri, Martin, Sommerer, Patrick, Maro, Geraldine, Yan, Songkai
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2020
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7079114/
https://www.ncbi.nlm.nih.gov/pubmed/31883398
http://dx.doi.org/10.1111/ejh.13378

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7079114/
https://www.ncbi.nlm.nih.gov/pubmed/31883398
http://dx.doi.org/10.1111/ejh.13378

Ejemplares similares